Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2465 - Clinical outcomes and treatment strategies of sarcomatoid carcinoma of the lung

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Yan Wang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii483-viii487. 10.1093/annonc/mdy290

Authors

Y. Wang

Author affiliations

  • Thoracic Surgery, Hebei Provincial Tumor Hospital, 50011 - Shijiazhuang/CN
More

Resources

Abstract 2465

Background

Sarcomatoid carcinoma of the lung is characterized by worse prognosis, and generally felt to be chemo-refractory compared with other non-small cell lung cancer. We conduct this retrospective study to investigate the clinical characteristics of patients with sarcomatoid carcinoma of the lung and determine the optimal treatment strategies.

Methods

We reviewed the medical records of 8176 patients with resected lung cancer in a single high-volume institution between 2008 and 2015. All patients with pathologically diagnosed sarcomatoid carcinoma were evaluated. Clinicopathologic data were analyzed using Kaplan-Meier analysis and Cox regression analysis. Subgroups stratified by pathological stage were analysed to determine the optimal treatment modality. We also conducted subgroup analysis of overall survival among pulmonary sarcomatoid carcinoma and other NSCLC patients.

Results

Kaplan-Meier and Cox regression analyses showed pathological stage (8th edition) is the independent prognostic factor (P = 0.001, HR = 2.601, 95%CI(1.447-4.675)) for pulmonary sarcomatoid carcinoma. Overall survival favored other NSCLC over PSC across subgroups. Male (HR = 0.695, 95%CI(0.505-0.955)), age above 60 years (HR = 0.622, 95%CI(0.417-0.928)), never-smoker (HR = 0.583, 95%CI(0.383-0.888)), patients who had no alcohol abuse history (HR = 0.597, 95%CI(0.416-0.856)), tumor size >5cm (HR = 0.700, 95%CI(0.492-0.995)), tumor stage T1 (HR = 0.383, 95%CI(0.167-0.877)), tumor location in peripheral (HR = 0.577, 95%CI(0.367-0.906)), or in both peripheral and central (HR = 0.626, 95%CI(0.424-0.923)), node stage N0 (HR = 0.599, 95%CI(0.403-0.891)), stage Ia(HR = 0.362, 95%CI(0.131-1.000)), stage Ib(HR = 0.450, 95%CI(0.278-0.729)), surgery alone (HR = 0.712, 95%CI(0.507-0.999)).

Conclusions

Pathological stage (8th edition) is independent prognostic factor for sarcomatoid carcinoma of the lung. Surgery followed by adjuvant chemotherapy should be considered for stage I pulmonary sarcomatoid carcinoma. Further prospective studies are needed to confirm these results.

Clinical trial identification

Legal entity responsible for the study

The Fourth Hospital of Hebei Medical University.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.